OR9I1

Across TCGA pan-cancer cohorts, OR9I1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated OR9I1 data layer compared with 11 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher OR9I1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR9I1 expression acts as an unfavorable survival marker.

CESC, LIHC, and LUSC are the cancer types where OR9I1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	All	0.227	0.742	.001	12	view →
LIHC	OS	Median	II,III,IV	0.010	0.716	<.001	12	view →
LUSC	OS	Median	II,III,IV	0.441	0.744	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

OR9I1–CESC (DFS)

Open the CESC breakdown →